BioPharmSignal logoBioPharmSignal

Company Profile

BioRestorative Stock Price, News & Catalysts

Ticker:
BRTX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

0.22 USD (-2.40%)

Close

Last updated: August 21, 2026

9.03M USD

Market cap

Why the stock is moving

As of Aug 21, 2026, BRTX closed down 2.40% at $0.2153. No new same-company headline was identified in the current news window.

Company overview

Business overview

BioRestorative Therapies is a regenerative medicine company focused on cell therapies and musculoskeletal repair. Its business centers on using biologic approaches to address spine and orthopedic conditions.

Geographic Base and Sector Classification

BioRestorative is headquartered in the United States and listed on NASDAQ. It sits in regenerative medicine and small-cap biotech.

Business Model Characteristics

The company depends on translational progress, platform validation, and financing to keep development moving. Investors typically watch preclinical or early clinical updates and the company's ability to prove a commercially relevant use case.

Position Within the Biotechnology Landscape

BioRestorative occupies a speculative regenerative-medicine niche within biotech. The stock is driven by platform credibility and the ability to turn cell therapy into a practical treatment path.

Future catalysts

  • BioRestorative’s catalysts are regenerative medicine, spinal-disc programs, and any update that shows the platform still has a path. The company remains highly dependent on clinical progress.

Recent news

  1. 01

    BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

  2. 02

    BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

  3. 03

    BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

  4. 04

    BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

  5. 05

    BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

ACHL

Achilles Therapeutics

ADAP

Adaptimmune Therapeutics plc

ACET

Adicet Bio

ALVR

AlloVir

ALLO

Allogene Therapeutics

ACLX

Arcellx

ATRA

Atara Biotherapeutics, Inc.

AUTL

Autolus Therapeutics plc

Frequently Asked Questions

What is the current stock price of BioRestorative (BRTX)?

BioRestorative (BRTX) most recently closed at 0.22 USD, a -2.40% move versus the previous session.

What is the market cap of BioRestorative (BRTX)?

BioRestorative currently has a market capitalization of 9.03M USD on BioPharmSignal.

What does BioRestorative do?

BioRestorative Therapies is a regenerative medicine company focused on cell therapies and musculoskeletal repair. Its business centers on using biologic approaches to address spine and orthopedic conditions.

On which exchange is BRTX stock listed?

BioRestorative (BRTX) is associated with NASDAQ, United States, Biopharma.

What is BioRestorative?

BioRestorative’s catalysts are regenerative medicine, spinal-disc programs, and any update that shows the platform still has a path.

Which conditions is BioRestorative targeting with BioRestorative?

BioRestorative’s catalysts are regenerative medicine, spinal-disc programs, and any update that shows the platform still has a path.

How does BioRestorative describe recent progress with BioRestorative?

BioRestorative’s catalysts are regenerative medicine, spinal-disc programs, and any update that shows the platform still has a path.

What is Therapies?

BioRestorative Therapies is a regenerative medicine company focused on cell therapies and musculoskeletal repair.